US private equity firm Bain Capital has reached an agreement to acquire Vitabiotics, the British maker of consumer healthcare brands including Perfectil, Wellman, Pregnacare and Jointace.
Deal and scale
The companies involved have not disclosed a formal price. UK media reports have, however, linked the transaction to a figure in the region of £900 million. Bain said the purchase covers the UK business and the wider VB group, including operations in India and Africa.
Founded in 1971 by Kartar Lalvani, Vitabiotics has been led by his son, Tej Lalvani, since 2015. Lalvani, who became a familiar public face during several seasons on the television programme Dragon’s Den, has been central to the group’s growth and brand development.
Plans and assurances
Bain described the acquisition as the start of a new growth phase, emphasising international expansion and accelerating product innovation. The new owner said there would be no immediate changes to day-to-day operations following the transaction.
"This direction is not about changing who we are; it is about accelerating what we can become,"
The comment came from Tej Lalvani, who added that Bain’s global resources present an opportunity to extend Vitabiotics’ reach while maintaining its scientific and quality standards.
"Vitabiotics is exactly the type of business we support: a trusted, science‑led brand platform with category leadership,"
Pawan Singh, a partner at Bain Capital, said the firm’s India team has experience in healthcare and consumer markets and intends to support the business’s next phase. Bain is already known for investments in consumer-facing firms globally.
Market context and implications
The sale comes after the Lalvani family initiated an auction process earlier this year. For Vitabiotics, the backing of a large private equity owner typically brings capital for international marketing, distribution deals and research and development — areas the buyer has specifically highlighted.
Key immediate implications include:
- Potential acceleration of overseas expansion, notably in markets where Vitabiotics already has a presence such as India, the Middle East, Africa and China.
- Access to Bain’s operational and capital resources to support innovation and scaling.
- Short-term continuity of management and operations, as publicly stated by the purchaser and seller.
Financial and strategic takeaways
While the precise financial terms remain undisclosed, media estimates approaching £900m would place Vitabiotics among the larger UK consumer healthcare exits to date. For the Lalvani family, the transaction represents monetisation of a long-established, science-led business founded more than five decades ago.
For the broader market, the deal underlines continuing appetite from US buyout houses for established UK consumer brands with international potential. It also reflects a trend in which financial sponsors seek category-leading, research‑backed companies that combine strong retail recognition with professional endorsements.
| Item | Detail |
|---|---|
| Buyer | Bain Capital |
| Seller / Founder | Lalvani family / Vitabiotics (founded 1971) |
| Reported valuation | c. £900m (reported by UK media) |
| Brands | Perfectil, Wellman, Pregnacare, Jointace |
Regulatory approvals and customary closing conditions will determine the timetable for completion. Until formal details are filed, investors and market watchers will be watching for confirmation of price and any planned strategic initiatives under Bain’s ownership.
The deal highlights the continuing value of trusted, science‑led consumer healthcare brands and signals fresh private capital flowing into UK-origin businesses with strong global recognition.
